Switch theme
Sign up to access all valuation multiples
Oscotec Inc is engaged in drug discovery for osteoporosis, arthritis, periodontal, dental health and cancer diseases.
1998
n/a
LTM Revenue n/a
LTM EBITDA n/a
$812M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Oscotec has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Oscotec achieved revenue of $23.2M and an EBITDA of $1.3M.
Oscotec expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Oscotec valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $3.4M | $23.2M | XXX | XXX | XXX |
| Gross Profit | $2.1M | $2.0M | XXX | XXX | XXX |
| Gross Margin | 61% | 9% | XXX | XXX | XXX |
| EBITDA | -$20.5M | $1.3M | XXX | XXX | XXX |
| EBITDA Margin | -606% | 6% | XXX | XXX | XXX |
| Net Profit | -$16.6M | -$16.5M | XXX | XXX | XXX |
| Net Margin | -493% | -71% | XXX | XXX | XXX |
| Net Debt | $3.0M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Oscotec's stock price is KRW 33500 (or $23).
Oscotec has current market cap of KRW 1.28T (or $873M), and EV of KRW 1.19T (or $812M).
See Oscotec trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $812M | $873M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Oscotec has market cap of $873M and EV of $812M.
Oscotec's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Oscotec's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Oscotec and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $812M | XXX | XXX | XXX |
| EV/Revenue | 35.1x | XXX | XXX | XXX |
| EV/EBITDA | 625.5x | XXX | XXX | XXX |
| P/E | 1461.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -44.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpOscotec's NTM/LTM revenue growth is n/a
Oscotec's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Oscotec's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Oscotec's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Oscotec and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 587% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -106% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 63% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 101% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oscotec acquired XXX companies to date.
Last acquisition by Oscotec was XXXXXXXX, XXXXX XXXXX XXXXXX . Oscotec acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Oscotec founded? | Oscotec was founded in 1998. |
| Where is Oscotec headquartered? | Oscotec is headquartered in South Korea. |
| Who is the CEO of Oscotec? | Oscotec's CEO is Mr. Jeong-Geun Kim. |
| Is Oscotec publicy listed? | Yes, Oscotec is a public company listed on KRX. |
| What is the stock symbol of Oscotec? | Oscotec trades under 039200 ticker. |
| When did Oscotec go public? | Oscotec went public in 2007. |
| Who are competitors of Oscotec? | Similar companies to Oscotec include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Oscotec? | Oscotec's current market cap is $873M |
| What is the current revenue growth of Oscotec? | Oscotec revenue growth between 2023 and 2024 was 587%. |
| Is Oscotec profitable? | Yes, Oscotec is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
